Orexo announces new Executive Management Team

Orexo announces new Executive Management Team

Following the completion of the Biolipox acquisition, Orexo has appointed a new
Executive Management Team. The new Executive Management Team consists of
Torbjörn Bjerke (President & CEO), Claes Wenthzel (Executive Vice President &
CFO), Thomas Lundqvist (Executive Vice President och Executive Advisor), Göran
Smedegård (Vice President Business Development & Commercial Development) and
Göran Tornling (Executive Vice President R&D).

”Orexo has a clear objective - to commercialize the product portfolio through
partnerships and licensing agreements with other pharmaceutical companies. The
main task for the Executive Management team is to prioritize and market the
projects that, for the time being, are considered to have the largest commercial
potential”, says Torbjörn Bjerke, President & CEO of Orexo AB.

Orexo´s new Executive Management Team - in short

Torbjörn Bjerke, President and Chief Executive Officer. Serves on the board of
directors of NeuroSearch AS and TopoTarget AS. Held the position as President
and CEO of Biolipox AB from January 2004 until November 2007.  Previously, he
has held Director of Research positions at AstraZeneca, and has served as
Executive Vice President of R&D at ALK-Abello. 

Claes Wenthzel, Executive Vice President & Chief Financial Officer. Joined the
Company in 2005. He serves on the board of directors of Stille AB and Stockholm
Asset Management AB. Prior to joining Orexo, Mr. Wenthzel has among other things
served as Vice President and Chief Financial Officer in Perbio Science AB.

Thomas Lundqvist, Executive Vice President and Executive Advisor. Mr. Lundqvist
is one of Orexo´s founders. Director of the Company between 1995 and 2003 and
its President between 1997 and 2002 and between December 2003 and April 2004. Mr
Lundqvist has a long experience working with the development of new
pharmaceuticals. Prior to joining Orexo, he held the position of President of
NeoPharma Production AB. In addition, Mr. Lundqvist has more than ten years of
experience working at the Swedish Medical Products Agency.

Göran Smedegård,Vice President Business Development & Commercial Development.
Prior to joining Orexo in 2003, he was Senior Investment Manager in the venture
capital fund Innoventus of which he was a co-founder. Dr. Smedegård has more
than 25 years of experience serving in leading positions at major pharmaceutical
companies including Director of Business Development at Pharmacia and Director
of Licensing at AstraZeneca. 

Göran Tornling, Executive Vice President Research & Development. Former Vice
President and Chief Medical Officer in Biolipox AB. Twenty years of research and
clinical experience in Respiratory Medicine at the Karolinska Institute. Most
recently a position as Medical Science Director at AstraZeneca R&D Lund, Sweden.



For more information, please contact:
Torbjörn Bjerke, President and CEO, Orexo AB
Tel: +46 (0)708-66 19 90
E-mail: torbjorn.bjerke@orexo.com

Claes Wenthzel, Executive Vice President & CFO, Orexo AB 
Tel: +46 (0)18-780 88 44, +46 (0)708-62 01 22
Email: claes.wenthzel@orexo.com

TO THE EDITORS 

About Orexo 

Orexo is a pharmaceutical company which focuses on identifying suboptimal
therapeutic characteristics of existing products and developing more efficient
and effective delivery methods for them. By combining approved active substances
with Orexo's drug delivery technologies it is possible to significantly enhance
their therapeutic value, such as providing quicker onset of action or ease of
administration. This business model is aimed at bringing products to market
faster with lower development risk and costs. 

Orexo, which has its global headquarters and development laboratories in Sweden,
currently operates across the world through development, licensing and
distribution agreements in all major markets. 

Orexo has a balanced portfolio with two products on the market, three in
registration and/or late stage clinical phase, one in clinical phase I, one in
formulation phase and two in early development phase. 

Orexo is listed on the Nordic List at the OMX Nordic Exchange Stockholm, Mid Cap
(ticker: ORX). 

www.orexo.com 

About Biolipox 

Biolipox is a Swedish research-intense pharmaceutical company that focuses on
developing novel, effective drugs for treating respiratory diseases and other
inflammatory diseases, such as asthma, chronic obstructive pulmonary disease
(COPD), rhinitis (hay fever), pain and arthritis (inflammatory joint diseases).
By drawing on its knowledge in the inflammatory research area, particularly
arachidonic acid metabolism, Biolipox has created a portfolio of potential
blockbusters in these therapeutic areas. The company has 52 employees and is
owned by Health Cap, Apax Partners, Sofinnova Partners, SLS Venture, Crédit
Agricole Private Equity, Auriga Partners and the scientific founders. 

www.biolipox.com